These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 30209920)

  • 1. Top-ten papers in fungal infection (2015-2017).
    Puerta-Alcalde P; Cardozo C; Soriano A; García-Vidal C
    Rev Esp Quimioter; 2018 Sep; 31 Suppl 1(Suppl 1):32-34. PubMed ID: 30209920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developments in the epidemiolgy of invasive fungal infections - implications for the empiric and targeted antifungal therapy.
    Hof H
    Mycoses; 2008; 51 Suppl 1():1-6. PubMed ID: 18471155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
    Fera MT; La Camera E; De Sarro A
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fungal biofilms: From bench to bedside.
    Iñigo M; Del Pozo JL
    Rev Esp Quimioter; 2018 Sep; 31 Suppl 1(Suppl 1):35-38. PubMed ID: 30209921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The changing face of fungal infections in health care settings.
    Fridkin SK
    Clin Infect Dis; 2005 Nov; 41(10):1455-60. PubMed ID: 16231257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Importance of mycoses in intra-abdominal infections].
    Blinzler L; Fischer K; Just HM; Heuser D
    Langenbecks Arch Chir; 1997; 382(4 Suppl 1):S5-8. PubMed ID: 9333708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Strategies for antifungal treatment failure in intensive care units].
    Arens C; Bernhard M; Koch C; Heininger A; Störzinger D; Hoppe-Tichy T; Hecker M; Grabein B; Weigand MA; Lichtenstern C
    Anaesthesist; 2015 Sep; 64(9):643-58. PubMed ID: 26349425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candida auris: Epidemiology, risk factors, virulence, resistance, and therapeutic options.
    de Cássia Orlandi Sardi J; Silva DR; Soares Mendes-Giannini MJ; Rosalen PL
    Microb Pathog; 2018 Dec; 125():116-121. PubMed ID: 30205192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [How do fungal infections "escape" treatment? Resistance and resistance mechanisms].
    Morschhäuser J
    Pharm Unserer Zeit; 2003; 32(2):124-8. PubMed ID: 12677965
    [No Abstract]   [Full Text] [Related]  

  • 11. [Nosocomial fungal infections, analysis of 149 cases].
    Liu ZY; Sheng RY; Li XL; Li TS; Wang AX
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):399-402. PubMed ID: 12820917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antifungal agents in the treatment of systemic infections: Relevance of mechanism of action, activity profile and resistances].
    Cuenca-Estrella M
    Rev Esp Quimioter; 2010 Dec; 23(4):169-76. PubMed ID: 21191554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Call to Action: How to Tackle Emerging Nosocomial Fungal Infections.
    Lionakis MS; Hohl TM
    Cell Host Microbe; 2020 Jun; 27(6):859-862. PubMed ID: 32526182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal drug resistance of pathogenic fungi.
    Kontoyiannis DP; Lewis RE
    Lancet; 2002 Mar; 359(9312):1135-44. PubMed ID: 11943280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential targets for the development of new antifungal drugs.
    Su H; Han L; Huang X
    J Antibiot (Tokyo); 2018 Nov; 71(12):978-991. PubMed ID: 30242283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The global problem of antifungal resistance: prevalence, mechanisms, and management.
    Perlin DS; Rautemaa-Richardson R; Alastruey-Izquierdo A
    Lancet Infect Dis; 2017 Dec; 17(12):e383-e392. PubMed ID: 28774698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal therapy in invasive fungal infections.
    Chen SC; Playford EG; Sorrell TC
    Curr Opin Pharmacol; 2010 Oct; 10(5):522-30. PubMed ID: 20598943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of antifungal susceptibility testing in patient management.
    Forrest G
    Curr Opin Infect Dis; 2006 Dec; 19(6):538-43. PubMed ID: 17075328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
    Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
    Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EPICO 3.0. Empirical antifungal therapy in critically-ill hematology patients.
    Llinares P; Ruiz I; Zaragoza R; Ferrer R; Rodríguez AH; Maseda E; Grau S;
    Rev Iberoam Micol; 2016; 33(4):206-215. PubMed ID: 27751781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.